FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.
What happened
FDA reviewed Epicur Pharma's website and found it markets compounded animal drugs with false or misleading claims about safety and effectiveness. FDA said the omeprazole injection suspension is compared to FDA-approved omeprazole drugs and the buprenorphine ER injection solution is compared to FDA-indexed buprenorphine drugs. FDA also said the site makes false statements about FDA oversight, GFI #256 compliance, 503B legality, and omits risk information.
What FDA found
Website claims falsely compare the custom-made omeprazole injection suspension to FDA-approved omeprazole drugs for horses, making the product's labeling false or misleading.
FD&C Act sections 502(a), 502(bb), and 201(n) (21 U.S.C. §§ 352(a), 352(bb), 321(n))Website claims falsely compare the custom-made buprenorphine ER injection solution to buprenorphine drugs FDA has listed for minor species, and the site falsely says FDA indexing is underway and misstates shelf life.
FD&C Act sections 502(a), 502(bb), and 201(n) (21 U.S.C. §§ 352(a), 352(bb), 321(n))Promotional materials for buprenorphine ER injection solution and omeprazole injection suspension do not communicate risk information.
FD&C Act section 201(n) (21 U.S.C. 321(n))Website falsely says the buprenorphine ER injection solution is compliant with FDA guidance GFI #256 and available for office use.
Website falsely says all Epicur tablets are manufactured to FDA specifications.
Website falsely suggests that section 503B allows animal drugs made in a human drug outsourcing facility to be dispensed as office stock.
FD&C Act section 503B (21 U.S.C. 353b)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific corrective steps, prevention steps, and supporting documentation. If corrections cannot be completed in that time, the company must explain the delay and give a completion date.
Who should pay attention
- veterinarians and laboratory animal facilities using compounded buprenorphine or omeprazole
- 503B outsourcing facilities that make animal drugs
- animal drug sponsors and pharmacies that compare products to FDA-approved or indexed drugs
This is a summary. Read the original letter on fda.gov.